House passes 21st Century Cures bill

Members of U.S. House of Representatives voted 344 to 77 today to approve the 21st Century Cures bill. It now goes to the Senate for consideration. Supporters like it because it provides more funds for the FDA and NIH. It has detractors, however, who are concerned about provisions that change the way drugs and devices are developed and approved. For example, it allows for the approval of antibiotics based on preclinical testing combined with limited human trials. It offers a faster pathway for approval but worries some that not enough safeguards will be in place. The bill also dumps some of the requirements drugmakers have for reporting physician payments, which also concerns some lawmakers. More from FierceBiotech

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.